{"id":"hypertonic-saline-3-bolus-administration","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypernatremia"},{"rate":null,"effect":"Hyperchloremia"},{"rate":null,"effect":"Phlebitis at infusion site"},{"rate":null,"effect":"Rebound intracranial hypertension"},{"rate":null,"effect":"Acute kidney injury"}]},"_chembl":{"chemblId":"CHEMBL2108783","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"When administered as a bolus, the high sodium concentration (3%) establishes an osmotic gradient across cell membranes and the blood-brain barrier. Water moves from areas of lower solute concentration (brain tissue, cells) into the higher concentration in the bloodstream, thereby reducing brain edema and intracranial pressure. This mechanism is particularly useful in acute neurological emergencies where rapid reduction of cerebral edema is critical.","oneSentence":"Hypertonic saline 3% creates an osmotic gradient that draws fluid from intracellular and interstitial spaces into the intravascular compartment, reducing intracranial pressure and cellular edema.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:37:16.673Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cerebral edema and elevated intracranial pressure"},{"name":"Traumatic brain injury"},{"name":"Acute stroke with cerebral edema"},{"name":"Intracranial hypertension"}]},"trialDetails":[{"nctId":"NCT05411991","phase":"PHASE4","title":"Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment","status":"COMPLETED","sponsor":"Vrije Universiteit Brussel","startDate":"2022-06-12","conditions":"Acute Heart Failure, Diuretics Drug Reactions","enrollment":107},{"nctId":"NCT02798601","phase":"NA","title":"Early Induced Hypernatremia for the Prevention and Management of Brain Edema","status":"WITHDRAWN","sponsor":"Hospital Pablo Tobón Uribe","startDate":"2017-01-18","conditions":"Head Trauma","enrollment":""},{"nctId":"NCT02887469","phase":"PHASE4","title":"Efficacy and Safety of Rapid Intermittent Compared With Slow Continuous Correction in Severe Hyponatremia Patients","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-08","conditions":"Hyponatremia Symptomatic","enrollment":178},{"nctId":"NCT01605357","phase":"PHASE1, PHASE2","title":"Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2012-07","conditions":"Traumatic Brain Injury, Subdural Hematoma, Cerebral Contusion","enrollment":""},{"nctId":"NCT02460510","phase":"NA","title":"Role of Hypertonic Saline Versus Mannitol in the Management of Raised Intracranial Pressure in Patients With ALF","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2014-06","conditions":"Acute Liver Failure","enrollment":52},{"nctId":"NCT02432157","phase":"PHASE1, PHASE2","title":"Safety and Feasibility of Hypertonic Saline Solution After Aneurysmal Subarachnoid Hemorrhage:","status":"UNKNOWN","sponsor":"Thomas Jefferson University","startDate":"2015-01","conditions":"Subarachnoid Hemorrhage, Cerebral Vasospasm, Hyponatremia","enrollment":50},{"nctId":"NCT01745081","phase":"PHASE4","title":"Comparison of 20% Mannitol and 3% Hypertonic Saline for Cerebral Relaxation During Elective Supratentorial Craniotomies","status":"UNKNOWN","sponsor":"Université de Sherbrooke","startDate":"2012-09","conditions":"Osmotherapy, Intracranial Pressure","enrollment":80},{"nctId":"NCT00316004","phase":"PHASE3","title":"Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI)","status":"TERMINATED","sponsor":"University of Washington","startDate":"2006-05","conditions":"Brain Injuries, Traumatic","enrollment":1331},{"nctId":"NCT01110655","phase":"NA","title":"The Efficacy of Oral Versus Intravenous Hypertonic Saline Administration in Runners With Exercise-Associated Hyponatremia","status":"UNKNOWN","sponsor":"Western States Endurance Run Research Foundation","startDate":"2009-06","conditions":"Exercise-associated Hyponatremia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Hypertonic saline 3% bolus administration","genericName":"Hypertonic saline 3% bolus administration","companyName":"Université de Sherbrooke","companyId":"universit-de-sherbrooke","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hypertonic saline 3% creates an osmotic gradient that draws fluid from intracellular and interstitial spaces into the intravascular compartment, reducing intracranial pressure and cellular edema. Used for Cerebral edema and elevated intracranial pressure, Traumatic brain injury, Acute stroke with cerebral edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}